Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zwitter Pharmaceuticals, including its related entity ZWI Pharmaceuticals, focuses on the application of zwitterionic materials (such as poly(carboxybetaine)) to drug delivery and vaccine platforms. Their technology is designed to create 'stealth' therapeutics that avoid immune detection and anti-drug antibody (ADA) responses, serving as an alternative to PEGylation. Current efforts include Z-LNP for mRNA delivery and zwitterionic-protein conjugates for metabolic and inflammatory diseases.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zwitter Pharmaceuticals.